Assessing the Presence of CT-DNA in Lymphoma Associated HLH

Recruiting Observational Study
Lymphoma Haemophagocytic Lymphohistiocytosis
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
12 (estimated)
Sponsor
Nottingham University Hospitals NHS Trust · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Haemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening blood disease which causes severe inflammation with symptoms similar to severe sepsis. It is hard to diagnose. The most common cause of HLH in adults is lymphoma (blood cancer). Outcomes for adults with HLH and cancer are serious, and most die after days or weeks because they have been diagnosed or treated too late. It is likely …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria: * Informed consent. * Age ≥18 years. * Clinically confirmed HLH. * High dose steroids and/or systemic anti-cancer therapy (SACT) for \<72 hours for the current episode of HLH (anakinra is not considered SACT). Prior steroid use \>14 days at the time of consent is permitted. * Pa…
Contacts

No contact information available.